Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles

Biomaterials

Volumn 34, Issue 11, 2013, Pages 2719-2730

  Pan, Limin ^a   Liu, Jianan ^a   He, Qianjun ^a   Wang, Lijun ^a   Shi, Jianlin ^a  

^a SHANGHAI INSTITUTE OF CERAMICS   (China)

Author keywords

DOX; MSNs; Multidrug resistance; Nuclear targeted; TAT peptide

Indexed keywords

DOX; MSNS; MULTIDRUG RESISTANCE; NUCLEAR-TARGETED; TAT PEPTIDE;

CHEMOTHERAPY; DRUG DELIVERY; DRUG INTERACTIONS;

CELLS;

DOXORUBICIN; DRUG CARRIER; NANOPARTICLE; SILICON DIOXIDE; TAT CONJUGATED MESOPOROUS SILICA NANOPARTICLE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL TRANSPORT; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; DRUG RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; LASER MICROSCOPY; PRIORITY JOURNAL; SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY;

APOPTOSIS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; MCF-7 CELLS; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; NEOPLASMS; SILICON DIOXIDE;

EID: 84873092879     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2012.12.040     Document Type: Article

References (53)

1. Larsen A.K., Escargueil A.E., Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Therapeut 2000, 85:217-229.
2. Eytan G.D. Mechanism of multidrug resistance in relation to passive membrane permeation. Biomed Pharmacother 2005, 59:90-97.
3. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005, 5:275-284.
4. Shapira A., Livney Y.D., Broxterman H.J., Assaraf Y.G. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updates 2011, 14:150-163.
5. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006, 5:219-234.
6. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008, 65:3145-3167.
7. Shukla S., Wu C., Ambudkar S. Development of inhibitor of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 2008, 4:205-223.
8. Fletcher J., Haber M., Henderson M., Norris M. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010, 10:147-156.
9. Ferry D., Traunecher H., Kerr D. Clinical trials of P-glycoprotein reversal in solid tumors. Eur J Cancer 1996, 32A:1070-1081.
10. Wang F., Wang Y.-C., Dou S., Xiong M.-H., Sun T.-M., Wang J. Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. ACS Nano 2011, 5:3679-3692.
11. Xiong X.-B., Lavasanifar A. Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 2011, 5:5202-5213.
12. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005, 103:405-418.
13. Meng H., Liong M., Xia T., Li Z., Ji Z., Zink J.I., et al. Engineered design of mesoporous silica nanoparticles to deliver doxorubicin and P-glycoprotein siRNA to overcome drug resistance in a cancer cell line. ACS Nano 2010, 4:4539-4550.
14. Chen A.M., Zhang M., Wei D., Stueber D., Taratula O., Minko T., et al. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 2009, 5:2673-2677.
15. Chen Y., Bathula S.R., Li J., Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J Biol Chem 2010, 285:22639-22650.
16. Sahay G., Alakhova D.Y., Kabanov A.V. Endocytosis of nanomedicines. J Control Release 2010, 145:182-195.
17. Iversen T.-G., Skotland T., Sandvig K. Endocytosis and intracellular transport of nanoparticles: present knowledge and need for future studies. Nano Today 2011, 6:176-185.
18. Gao H., Shi W., Freund L.B. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci U S A 2005, 102:9469-9474.
19. Jiang W., Kim B.Y.S., Rutka J.T., Chan W.C.W. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol 2008, 3:145-150.
20. Jin H., Heller D.A., Sharma R., Strano M.S. Size-dependent cellular uptake and expulsion of single-walled carbon nanotubes: single particle tracking and a generic uptake model for nanoparticles. ACS Nano 2009, 3:149-158.
21. Chavanpatil M.D., Khdair A., Gerard B., Bachmeier C., Miller D.W., Shekhar M.P.V., et al. Surfactant-polymer nanoparticles overcome P-glycoprotein-mediated drug efflux. Mol Pharm 2007, 4:730-738.
22. Ganta S., Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol Pharm 2009, 6:928-939.
23. Fan Y., Li C., Cao H., Li F., Chen D. The intranuclear release of a potential anticancer drug from small nanoparticles that are derived from intracellular dissociation of large nanoparticles. Biomaterials 2012, 33:4220-4228.
24. Wente S.R. Gatekeepers of nucleus. Science 2000, 288:1374-1377.
25. Tkachenko A.G., Xie H., Coleman D., Glomm W., Ryan J., Anderson M.F., et al. Multifunctional gold nanoparticle-peptide complexes for nuclear targeting. J Am Chem Soc 2003, 125:4700-4701.
26. Sun Z., Wang Y., Wei Y., Liu R., Zhu H., Cui Y., et al. Ag cluster-aptamer hybrid: specifically marking the nucleus of live cells. Chem Commun 2011, 47:11960-11962.
27. Chen F., Gerion D. Fluorescent CdSe/ZnS nanocrystal-peptide conjugates for long-term, nontoxic imaging and nuclear targeting in living cells. Nano Lett 2004, 4:1827-1832.
28. Xu C., Xie J., Kohler N., Walsh E.G., Chin Y.E., Sun S. Monodisperse magnetite nanoparticles coupled with nuclear localization signal peptide for cell-nucleus targeting. Chem Asian J 2008, 3:548-552.
29. Kubitscheck U., Grünwald D., Hoekstra A., Rohleder D., Kues T., Siebrasse J.P., et al. Nuclear transport of single molecules. J Cell Biol 2005, 168:233-243.
30. Slowing I.I., Vivero-Escoto J.L., Wu C.W., Lin V.S.Y. Mesoporous silica nanoparticles as controlled release drug delivery and gene transfection carriers. Adv Drug Deliv Rev 2008, 60:1278-1288.
31. Slowing I.I., Trewyn B.G., Giri S., Lin V.S.Y. Mesoporous silica nanoparticles for drug delivery and biosensing applications. Adv Funct Mater 2007, 17:1225-1236.
32. Tang F., Li L., Chen D. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery. Adv Mater 2012, 24:1504-1534.
33. He Q., Gao Y., Zhang L., Zhang Z., Gao F., Ji X., et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011, 32:7711-7720.
34. Chen Y., Chen H.R., Zeng D.P., Tian Y.B., Chen F., Feng J.W., et al. Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano 2010, 4:6001-6013.
35. He Q., Zhang Z., Gao Y., Shi J., Li Y. Intracellular localization and cytotoxicity of spherical mesoporous silica nano- and microparticles. Small 2009, 5:2722-2729.
36. Gao Y., Chen Y., Ji X., He X., Yin Q., Zhang Z., et al. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. ACS Nano 2011, 5:9788-9798.
37. Yang P., Gai S., Lin J. Functionalized mesoporous silica nanoparticles for controlled drug delivery. Chem Soc Rev 2012, 41:3679-3698.
38. Gai S., Yang P., Li C., Wang W., Dai Y., Niu N., et al. Synthesis of magnetic, up-conversion luminescent, and mesoporous core-shell-structured nanocomposites as drug carriers. Adv Func Mater 2010, 20:1166-1172.
39. 2 nanocomposite fibers for anti-cancer drug delivery and cell imaging. Adv Func Mater 2012, 22:2713-2722.
40. Yang P., Quan Z., Hou Z., Li C., Kang X., Cheng Z., et al. A magnetic, luminescent and mesoprous core-shell structured composite materials as drug carrier. Biomaterials 2009, 30:4786-4795.
41. Kang X., Cheng Z., Yang D., Ma P., Shang M., Peng C., et al. Design and synthsis of multifunctional drug carriers based on luminescent rattle-type mesoporous silica microspheres with a thermosensitive hydrogel as a controlled switch. Adv Func Mater 2012, 22:1470-1481.
42. Popat A., Liu J., Lu G., Qiao S. A pH-responsive drug delivery system based on chitosan coated mesoporous silica nanoparticles. J Mater Chem 2012, 22:11173-11178.
43. Hartono S., Gu W., Kleitz F., Liu J., He L., Middelberg A., et al. Poly-L-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery. ACS Nano 2012, 6:2104-2117.
44. Popat A., Ross B., Liu J., Jambhrunkar S., Kleitz F., Qiao S. Enzyme-responsive controlled release of covalently bond prodrug from functional mesoporous silica nanospheres. Angew Chem Int Ed 2012, 51:1-5.
45. Mamaeva V., Rosenholm J.M., Bate-Eya L.T., Bergman L., Peuhu E., Duchanoy A., et al. Mesoporous silica nanoparticles as drug delivery systems for targeted inhibition of notch signaling in cancer. Mol Ther 2011, 19:1538-1546.
46. Huang I.-P., Sun S.-P., Cheng S.-H., Lee C.-H., Wu C.-Y., Yang C.-S., et al. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance. Mol Cancer Ther 2011, 10:761-769.
47. Pan L., He Q., Liu J., Chen Y., Ma M., Zhang L., et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J Am Chem Soc 2012, 134:5722-5725.
48. Kobler J., Bein T. Porous thin films of functionalized mesoporous silica nanoparticles. ACS Nano 2008, 2:2324-2330.
49. Nitin N., LaConte L., Rhee W., Bao G. Tat peptide is capable of importing large nanoparticles across nuclear membrane in digitonin permeabilized cells. Ann Biomed Eng 2009, 37:2018-2027.
50. Yuan H., Fales A., Vo-Dinh T. TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. J Am Chem Soc 2012, 134:11358-11361.
51. Nakase I., Akita H., Kogure K., Gräslund A., Langel ü., Harashima H., et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res 2011, 45:1132-1139.
52. Khafagy E.-S., Morishita M. Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 2012, 64:531-539.
53. Cohen G.M. Caspases: the executioners of apoptosis. Biochem J 1997, 326:1-16.